AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Venclexta (venetoclax) by Quarter
Venclexta (venetoclax) — U.S. reported growth YoY (%) (%)
AbbVie Venclexta (venetoclax): 14.8% in Q2 2026, up 7.4 pts from a year earlier.
Latest, Q2 2026
14.8%
Period ended Jun 30, 2026
Change on a year earlier
+7.4 pts
7.4% in Q2 2025
History
26 quarters
Since Q4 2019
Sources
26
Documents cited below
Where the Q2 2026 figure comes from
“|| Venclexta | 369 | 402 | 771 | 14.8 | 8.8 | 11.6 | 5.0 | 9.6”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Venclexta (venetoclax) (%), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/venclexta-us-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.